A phase I parallel, single-centre, double-blind, randomized, placebo-controlled, single-dose, two-period, two-treatment, two-sequence, crossover study of Lixisenatide in healthy subjects.
Latest Information Update: 31 May 2016
At a glance
- Drugs Lixisenatide (Primary)
- Indications Diabetes mellitus
- Focus Pharmacodynamics
- 31 May 2016 New trial record